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3Department of Vascular Surgery, Cleveland Clinic, Cleveland, OH, and 4Division of Vascular Surgery,
Harbor UCLA, Torrance, CA, USAObjective. To compare the outcome of patients with small abdominal aortic aneurysms (AAA) treated in a prospective trial
of endovascular aneurysm repair (EVAR) to patients randomized to the surveillance arm of the UK Small Aneurysm Trial.
Method. All patients with small AAA (%5.5 cm diameter) treated with a stent graft (EVARsmall) in the multicenter
AneuRx clinical trial from 1997 to 1999 were reviewed with follow up through 2003. A subgroup of patients (EVARmatch)
who met the age (60–76 years) and aneurysm size (4.0–5.5 cm diameter) inclusion criteria of the UK Small Aneurysm Trial
were compared to the published results of the surveillance patient cohort (UKsurveil) of the UK Small Aneurysm Trial
(NEJM 346:1445, 2002). Endpoints of comparison were aneurysm rupture, fatal aneurysm rupture, operative mortality,
aneurysm related death and overall mortality. The total patient years of follow-up for EVAR patients was 1369 years and for
UK patients was 3048 years. Statistical comparisons of EVARmatch and UKsurveil patients were made for rates per 100
patient years of follow up (/100 years) to adjust for differences in follow-up time.
Results. The EVARsmall group of 478 patients comprised 40% of the total number of patients treated during the course of
the AneuRx clinical trial. The EVARmatch group of 312 patients excluded 151 patients for age!60 orO76 years and 15
patients for AAA diameter!4 cm. With the exception of age, there were no significant differences between EVARsmall and
EVARmatch in pre-operative factors or post-operative outcomes. In comparison to the UKsurveil group of 527 patients, the
EVARmatch group was slightly older (70G4 vs. 69G4 years, pZ0.009), had larger aneurysms (5.0G0.3 vs. 4.6G0.4 cm,
p!0.001), fewer women (7 vs. 18%, p!0.001), and had a higher prevalence of diabetes and hypertension and a lower
prevalence of smoking at baseline. Ruptures occurred in 1.6% of EVARmatch patients and 5.1% of UKsurveil patients; this
difference was not significant when adjusted for the difference in length of follow up. Fatal aneurysm rupture rate, adjusted
for follow up time, was four times higher in UKsurveil (0.8/100 patient years) than in EVARmatch (0.2/100 patient years,
p!0.001); this difference remained significant when adjusted for difference in gender mix. Elective operative mortality rate
was significantly lower in EVARmatch (1.9%) than in UKsurveil (5.9%, p!0.01). Aneurysm-related death rate was two
times higher in UKsurveil (1.6/100 patient years) than in EVARmatch (0.8/100 patient years, pZ0.03). All-cause mortality
rate was significantly higher in UKsurveil (8.3/100 patient years) than in EVARmatch (6.4/100 patient years, pZ0.02).
Conclusions. It appears that endovascular repair of small abdominal aortic aneurysms (4.0–5.5 cm) significantly reduces
the risk of fatal aneurysm rupture and aneurysm-related death and improves overall patient survival compared to an
ultrasound surveillance strategy with selective open surgical repair.Keywords: Endovascular; Surveillance; Abdominal aortic aneursym; Surgery.Introduction
The risk of rupture of abdominal aortic aneurysms is
related to aneurysm size.1 While there is little
disagreement on the need to repair large aorticthe European Society for Vascular Surgery, Innsbruck,
ember 17, 2004.
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with small aneurysms is unclear. Two prospective
randomized clinical trials of good risk patients with
small (%5.5 cm) aortic aneurysms found no difference
in overall survival rates between patients treated with
early elective surgical repair compared to those
followed with ultrasound surveillance.2,3 While the
effectiveness of early surgery or surveillance in
preventing aneurysm rupture was not an end-point
in these trials, they are cited as evidence that
aneurysms smaller than 5.5 cm have a very low riskEur J Vasc Endovasc Surg 29, 496–503 (2005)
doi:10.1016/j.ejvs.2005.03.003, available online at http://www.sciencedirect.com onved.
Small AAA: EVAR vs Surveillance 497of rupture.4 Since, the operative mortality for elective
open surgical repair of abdominal aneurysms is 3–
6%,3,5–8 it is commonly recommended that small
aneurysms should not be treated unless they enlarge
or become symptomatic.
However, the effectiveness of surveillance in pre-
venting aneurysm rupture has not been established.
Despite close monitoring and early surgery when
indicated, rupture occurred in the surveillance group
of both prospective clinical trials.2,3,9 Brown and
Powell found that in a cohort of 2257 patients with
small aneurysms, including 1090 patients from UK
Small Aneurysm Trial, there were 2.7 aneurysm
ruptures per 100 person years of follow up. In other
words, in 1.7 years, 4.6% of patients (69 of 1509
patients) with small aneurysms, 4.0–5.5 cm in diam-
eter, sustained rupture.10 In addition, ineligible
patients followed outside the UK trial had a higher
risk of aneurysm rupture than randomized patients.11
This suggests the need for better strategies to prevent
aneurysm rupture in patients with small aneurysms.
Since, completion of the prospective small aneurysm
trials, endovascular aneurysm repair (EVAR) has
gained acceptance in the treatment of suitable patients
with infrarenal aortic aneurysms. Endovascular repair
compares favorably to open surgical repair in short
and mid-term analysis12–15 and may have long-term
benefits with reduced aneurysm related death.16 Two
recent prospective randomized clinical trials compar-
ing EVAR to open surgical repair found a three- to
four-fold reduction in 30 day operative mortality in
patients undergoing endovascular aneurysm repair.17,
18 Favorable results with EVAR have also been
demonstrated in patients with small aneurysms.19,20
However, extending the use of EVAR to patients with
small aneurysms has been questioned.21
The purpose of this study is to determine whether
endovascular repair (EVAR) is more effective than
ultrasound surveillance in preventing aneurysm rup-
ture and death in patients with small AAA. In order to
address this question, we compared patients with
small AAA treated with EVAR in a prospective,
controlled clinical trial14,22 to patients with small
AAA randomized to ultrasound surveillance in the
prospective UK Small Aneurysm Trial.2,9Methods
We reviewed the pre-operative maximal aortic aneur-
ysm diameter of all 1193 patients treated during the
course of the multicenter AneuRx clinical trial from
1996 to 1999. Patients treated with the commercially
available version of the AneuRx stent graft who had apre-operative aortic aneurysm diameter of 5.5 cm or
less were selected for study. Patients treated with the
stiff prototype device and those treated off-protocol in
the high-risk patient cohort14 were excluded from this
analysis. The group of 478 patients (EVARsmall)
included 151 patients who would not have been
candidates for the UK Small Aneurysm Trial on the
basis of age less than 60 years or age greater than 76
years and 15 patients who would not have been
candidates for the UK trial because aneurysm diam-
eter was smaller than 4.0 cm. Exclusion of these 166
patients resulted in a cohort of 312 patients (EVAR-
match) which was used for comparison to the UK
Small Aneurysm Trial. Follow-up information was
complete for the EVARsmall and EVARmatch groups
through August 2003 and results for the entire group
of 1193 patients has been published.22,23 The results of
patients entered into the UK Small Aneurysm Trial
from 1991 to 1995 were published in 19982 and in
2002.9 This multicenter, prospective clinical trial of 60–
76 year old patients with small aneurysms (diameterZ
4.0–5.5 cm) who were fit for elective open surgical
repair, randomly assigned 527 patients to ultrasound
surveillance and compared them to 563 patients
randomly assigned to early elective open surgery.24
The patients in the UK surveillance group, according
to protocol, were offered open surgical repair if the
aneurysm enlarged to a diameter greater than 5.5 cm,
enlarged by more than 1 cm per year, became tender or
became symptomatic. In this report, we compared the
published results of the 527 patients in the UK
surveillance group (UKsurveil) to the results of the
matched subgroup of patients treated with endovas-
cular repair (EVARmatch).
The primary endpoints of comparison were (a)
rupture, (b) fatal rupture, (c) elective operative
mortality (d) aneurysm related death rate and (e)
overall survival. In order to standardize comparisons,
endpoints were calculated as a rate per 100 patient
years of follow-up, in accordance with the method-
ology used in the UK Small Aneurysm Trial.9
Aneurysm related death was defined as the sum of
30-day mortality and secondary procedure mortality,
including surgical conversion mortality, rupture and/
or aneurysm-repair related mortality.
Baseline characteristics of the different patient
cohorts include the mean and standard deviation for
quantitative variables and percentages for binary
variables. Statistical comparisons between the EVAR-
match and UKsurveil cohorts for the four outcomes:
ruptures, fatal ruptures, AAA related death and all-
cause mortality were based on the number of events
per 100 patient years of follow-up. Since, the EVAR-
match and UKsurveil groups were significantlyEur J Vasc Endovasc Surg Vol 29, May 2005
Table 1. Baseline characteristics in the study groups
EVARsmall* (nZ478) EVARmatch† (nZ312) UKsurveil‡ (nZ527) p-value§
Mean age (years) 73 (SD 7) 70 (SD 4) 69 (SD 4) 0.009
Gender (male:female) 90%/10% 93%/7% 82%/18% !0.001
AAA diameter (cm) 5.0 (SD 0.4) 5.0 (SD 0.3) 4.6 (SD 0.4) !0.001
Ever smoked 82% 87% 94% !0.001
Diabetes 12% 13% 3% !0.001
Hypertension 66% 63% 40% !0.001
COPD 27% 28% n.a.
* Endovascular repair patients with small aneurysms in AneuRx clinical trial (%5.5 cm).
† Subset of endovascular small aneurysm patients who met the age and aneurysm diameter inclusion criteria of the UK Small Aneurysm
Trial surveillance group.
‡ Surveillance group from UK Small Aneurysm Trial published in N Eng J Med 2002;345:1445.
§ Comparison between EVARmatch and UKsurveil groups.
C. K. Zarins et al.498different in gender mix, gender-specific rates per 100
patient years of follow-up were calculated for both
patient cohorts when possible. When the event rates
were stratified by gender for the UKsurveil group,
these rates were directly standardized to the EVAR-
match gender-specific years of follow-up. This allowed
comparison of the UKsurveil cohort to the EVARmatch
group with adjustment for gender differences. The
comparison of operative mortality rates did not need
to be adjusted for differences in length of follow-up
since these events are captured acutely (within 30 days
of treatment). The normal approximation to the
binomial was used to test for differences between
these endpoints.25ResultsEndovascular small aneurysm groups
The 478 patients with aneurysms 5.5 cm or smaller
(EVARsmall) comprised 40% of the total number of
1193 patients treated during the course of the
AneuRx clinical trial. A total of 166 patients (35%)
small aneurysm patients in the AneuRx trial did
not meet the inclusion criteria of the UK Small
Aneurysm Trial on the basis of age (nZ151) or
aneurysm size (nZ15), leaving 312 patients in the
EVARmatch group. Patient characteristics of the
EVARsmall and EVARmatch groups are shown inTable 2. Study results after EVAR and ultrasound surveillance of sm
EVARsmall
Total patient-years of follow-up 1369
Mean years of follow-up (SD, range) 2.9 (1.2, 0–5)
Total ruptures 1.3%
Fatal ruptures 0.4%
Elective operative mortality* 1.3%
Total AAA related death 1.7%
Total mortality 19%
* EVARmatch rate is significantly lower than UKsurveil (pZ0.001).
Eur J Vasc Endovasc Surg Vol 29, May 2005Table 1. The EVARsmall group was 3 years older
than EVARmatch (73G7 vs. 70G4 years). Other-
wise, there were no significant differences between
the EVAR groups as shown on Table 1. Mean pre-
operative aneurysm diameter was 5.0 cm in both
groups. Mean duration of follow up was 2.9G1.2
years (range 0–5 years) with no difference in follow
up time between the two endovascular groups
(Table 2). The number of patient years of follow up
in the EVARmatch group was 898 patient years
and in the EVARsmall group was 1369 patient
years. This difference is due to the greater number
of patients in the EVARsmall group.EVARmatch vs. UK surveillance groups
Comparisons of the baseline characteristics of the
EVARmatch group to the UKsurveil group are shown
on Table 1. The EVARmatch group was 1 year older
(70G4 vs. 69G4 years, pZ0.009) and had fewer
women (7 vs. 18%, p!0.001) than the UKsurveil
group. Baseline aneurysm diameter was larger in
EVARmatch (5.0G0.3 vs. 4.6G0.4 cm, p!0.001) than
in UKsurveil. There was a higher prevalence of
diabetes and hypertension and lower prevalence of
smoking history among the EVARmatch patients (p!
0.001). Duration of follow up was greater in the UK
trial with a mean duration of 5.8 years with a range of
0–10 years.9all aneurysms
EVARmatch UKsurveil
898 3048
2.9 (1.2, 0–5) 5.8 (n/a, 0–10)
1.6% 5.1%
0.6% 4.6%
1.9% 5.9%
2.2% 9.5%
18% 48%
Small AAA: EVAR vs Surveillance 499Aneurysm rupture
Aneurysm ruptures occurred in both the EVAR small
aneurysm and UK surveillance groups. A total of six of
478 patients (1.3%) in the EVARsmall group sustained
aneurysm rupture. Two of these ruptures were early
ruptures and occurred during the implant procedure.
There were four late ruptures, occurring between 20
and 48 months. One of the two early ruptures is
included in the EVARmatch group (1 year rupture rate
of 0.3%) and all four late ruptures occurred among
EVARmatch patients. Thus, a total of five of 312
patients (1.6%) in the EVARmatch group sustained
aneurysm rupture (Table 2).
During the course of the UK clinical trial (ending in
June 1998), 25 aneurysms ruptured with an average
risk of rupture of 1.6% per year, including small
aneurysms that had enlarged to O5.5 cm or become
symptomatic.9 Fifteen of these ruptures were in
aneurysms 4.0–5.5 cm in diameter at last measurement
with a mean risk of rupture of 1.0% per year. Since,
rupture was not a primary endpoint of the UK trial,
the timing and distribution of ruptures between the
surveillance and early surgery groups was not
reported, so that 1-year rupture rates could not be
compared. A total of 27 of 527 UK surveillance patients
(5.1%) sustained rupture by the end of UK patient
follow up (August 2001). Adjusted for the difference in
length of follow up, the rupture rate was slightly
higher, but not statistically significantly different, in
the UK surveillance patients (0.9/100 patient years)
compared to the EVARmatch patients (0.6/100 patient
years, ns) (Table 3).Fatal ruptures
Fatal ruptures, including patients who sustained
rupture and underwent emergent surgical repair
occurred in two of 478 patients (0.4%) in the
EVARsmall group. Both patients were in the EVAR-
match group, which had a fatal rupture rate of 0.6%
(two of 312 patients). Fatal ruptures occurred in 24 of
527 patients (4.6%) in the UK surveillance group
during the follow up period (Table 2). Of these, 21
were unrepaired aneurysms undergoing surveillanceTable 3. Study endpoints after EVER and ultrasound surveillance of
EVARsmall EV
Total ruptures/100 patients years 0.4 0.6
Fatal ruptures/100 person years 0.1 0.2
AAA related deaths/100 person years 0.6 0.8
All-cause death/100 person years 6.6 6.4and three were aneurysms that had undergone open
repair. Overall, 8% of all deaths in the surveillance
group were due to rupture of unrepaired aneurysms
and 1% of deaths were due to rupture of repaired
aneurysms. In the EVAR group, 4% of all deaths were
due to ruptured aneurysms (Table 4). The fatal rupture
rate/100 patient years of follow up was four times
higher among UK surveillance patients (0.8/100
patient years) than among EVARmatch patients (0.2/
100 patient years, p!0.001) (Table 3). In view of the
fact that the risk of fatal rupture was four times higher
in women than in men in the UK trial,9 we adjusted the
UKsurveil rate to correct for differences in lengths of
follow-up for each gender. Using direct standardiz-
ation to adjust the UK length of follow-up to the
EVARmatch length of follow-up, the UK rate
decreased to 0.7/100 patient years but remained
significantly higher than the EVARmatch group (pZ
0.05).Elective operative mortality
Elective 30 day operative mortality rate for the
EVARmatch group was 1.9%, significantly lower (p!
0.01) than the 5.9% operative mortality rate for the 355
patients in the UK surveillance group who underwent
elective open surgical repair.9 There was no significant
difference in operative mortality between women (0%,
0/23) and men (2.1%, 6/289) in the EVARmatch group.
Gender specific operative mortality data was not
published for the UK Small Aneurysm Trial, therefore,
these rates could not be further adjusted to account for
gender differences.Aneurysm related death rate
The total aneurysm-related death rate for EVARmatch
patients was 2.2%. The total aneurysm related death
rate among UKsurveil patients was 9.5%. Adjusted for
the difference in length of follow up, AAA related
death was two times higher in UK surveillance
patients (1.6/100 patient years) than in EVARmatch
patients (0.8/100 patient years, pZ0.03) (Table 3).
There was no significant difference in the AAA related
death rates between women (0%, 0/23) and mensmall aneurysms (per 100 patient years of follow-up)
ARmatch UKsurveil p-value
(EVARmatch vs. UK)
0.9 ns
0.8 0.001
1.6 0.03
8.3 0.02
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Table 4. Cause of death EVARmatch vs. UKsurveil
EVARmatch UKsurveil
Total deaths 57 254
Cardiovascular—total 30 (53%) 172 (68%)
MI 11 (19%) 48 (19%)
Stroke 3 (5%) 12 (5%)
Ruptured TAA 2 (4%) 11 (4%)
Ruptured AAA 2 (4%) 24* (9%)
Other cardiovascular 12 (21%) 52 (20%)
Cancer—total 10 (18%) 44 (17%)
Lung cancer 5 (9%) 13 (5%)
Other cancer 5 (9%) 31 (12%)
Other 16† (28%) 37 (15%)
Unknown 1 (2%) 1 (!1%)
* Twenty-one ruptures occurred while patients were undergoing
surveillance, and three occurred after open repair.
† Ten of the 16 were pulmonary including: COPD, pneumonia,
emphysema and respiratory.
C. K. Zarins et al.500(2.4%, 7/289) in the EVARmatch group. Gender
specific data regarding AAA related death was not
published for the UK trial, therefore, these rates could
not be adjusted to account for gender differences.All-cause mortality
All-cause mortality rate among EVARmatch patients
was 18% while all-cause mortality among UKsurveil
patients was 48%. The causes of death for the two
groups are similar as shown in Table 4. Deaths due to
thoracic aneurysm rupture were the same in both
groups (4% in each). However, deaths due to abdomi-
nal aortic rupture were higher in UKsurveil (9.4%)
than in EVARmatch (3.5%). Adjusted for the difference
in length of follow up, the all-cause mortality rate was
lower among EVARmatch patients (6.4/100 patient
years) than among UKsurveil patients (8.3/100 patient
years, pZ0.02). These rates/100 patient years of
follow-up did not change upon adjusting for gender
differences.Discussion
The primary objective of elective aneurysm repair is to
prevent aneurysm rupture and death. However, the
results of surgical repair of aortic aneurysms are rarely
reported in terms of effectiveness in preventing
rupture but rather only in terms of operative mortality
rates and overall patient survival.5–8 It is usually
assumed that the risk of rupture has been eliminated
following open surgical repair, although late aneur-
ysm ruptures and deaths have been reported to occur
following open repair with a frequency of 1% or
more.7,26 In the UK Small Aneurysm Trial, 1% of allEur J Vasc Endovasc Surg Vol 29, May 2005deaths in the surveillance group were due to aneur-
ysm rupture in patients who had been successfully
treated with open repair.9 Endovascular aneurysm
repair, on the other hand, is usually evaluated in terms
of its effectiveness in preventing aneurysm rupture
and aneurysm related death and includes a number of
indirect measures which are thought to reflect the risk
of rupture, such as endoleak, device migration and
aneurysm enlargement.27 These differences in primary
endpoint focus have made comparisons between open
and endovascular repair more complex. While there is
little controversy with regard to the need to repair
large aortic aneurysms by open or endovascular
techniques, these differences have contributed to
uncertainty on the best way to treat small aneurysms.
Both the UK Small Aneurysm Trial and ADAM
study randomly assigned patients to ultrasound
surveillance or elective open surgery and used all-
cause mortality (overall survival) as the primary
endpoint to conclude that long term survival was not
improved by early surgery compared to ultrasound
surveillance. Despite including only young, good risk
patients who were fit for surgery, overall mortality rate
for these small aneurysm patients was high with a
mean duration of survival of only 6.5 years. By the end
of the follow up period, 48% of UK surveillance
patients had died, as had 43% of early surgery
patients.9 This is consistent with the well known fact
that patients with aortic aneurysms frequently have
multiple comorbidities and have a reduced life
expectancy compared to an age-matched normal
population.28 Thus, overall survival can be expected
to be a poor discriminator of different treatment
strategies to prevent aneurysm rupture. This is
illustrated by the fact that despite finding a long
term survival advantage (after 8 years) for early
surgery patients in the UK trial, this benefit was
attributed to smoking cessation and life style changes
rather than to the aneurysm treatment strategy.9
Since, the primary objective of aneurysm treatment
is to prevent rupture and death, more meaningful
endpoints to evaluate effectiveness of treatment are
aneurysm rupture rate and aneurysm-related mor-
tality.16 Although aneurysm rupture was not a
primary endpoint in the UK and ADAM trials, both
studies reported a low rupture rate (1.0 and 0.6% per
year, respectively) for small aneurysms and suggested
that small aneurysms could be safely followed with
ultrasound surveillance.2,3,9 Nonetheless, abdominal
aortic aneurysm ruptures were responsible for 9% of
the deaths in the UK surveillance group and 4% of the
patients in the UK early surgery group, indicating that
aortic aneurysm rupture and death is a significant
problem for patients with small aneurysms. In
Small AAA: EVAR vs Surveillance 501addition, both treatment groups experienced deaths
directly attributable to the aneurysm or its treatment
19% of deaths in the surveillance group and 15% of the
deaths in the early surgery group due to rupture of the
aneurysm or its surgical repair.9
In this study, we sought to determine whether early
endovascular repair of small aortic aneurysms offered
an advantage over ultrasound surveillance strategy by
comparing patients with small aneurysms in the
AneuRx clinical trial to those in the UK Small
Aneurysm Trial. In doing so, it should be noted that
there are significant differences between the two trials.
The prospective, non-randomized, multicenter
AneuRx clinical trial was conducted from 1996 to
1999, after patient entry into the prospective, random-
ized UK Small Aneurysm Trial had been completed in
1995. Patient selection criteria were different and
endpoints and objectives of the two trials were
different. Nonetheless, both studies have comprehen-
sive and long term follow up of well-characterized
patients with infrarenal abdominal aortic aneurysms.
In the AneuRx clinical trial, 40% of the patients treated
had small aneurysms (5.5 cm or smaller). We made
every effort to match the AneuRx small aneurysm
patient population to the inclusion criteria of the UK
Small Aneurysm Trial by excluding 151 patients for
age less than 60 years or age greater than 76 years as
well as 15 patients for aneurysm diameter less than
4.0 cm. Despite this, there were important differences
between the matched EVAR and UK surveillance
groups with respect to age, comorbidities and gender
distribution. Patients in the AneuRx trial were slightly
older, had more comorbidities and had larger aneur-
ysms than patients in the UK trial. This difference
would tend to balance the analysis in favor of
surveillance. On the other hand, the UK clinical trial
enrolled proportionally twice as many women as the
AneuRx trial. Since, rupture and death from rupture
was four-fold higher among women than among men
in the UK trial,9 the difference in gender distribution
may partially account for the different outcomes. We
adjusted our analysis for gender difference and found
that differences in outcomes remained statistically
significant. In addition, there was a significant
difference in the duration of follow up between the
groups with a mean follow up of 5.8 years in the UK
surveillance group and mean follow up of only 2.9
years in the matched EVAR group. In order to correct
for this difference, statistical comparisons of endpoints
were made in terms of 100 patient years of follow up.
While this allows valid comparisons to be made with
the available data, longer follow up may show an
increasing rate of late complications for endovascular
repair, which could invalidate the conclusions.However, thus far there is no evidence for such an
increase in late complications with flat Kaplan–Meier
curves for freedom from aneurysm rupture, aneurysm
related death and surgical conversion from 3 to 5 years
among the 1193 AneuRx clinical trial patient.23
We found that the risk of fatal aneurysm rupture
and aneurysm related death as well as elective
operative mortality and all-cause mortality were all
significantly lower in patients treated with endovas-
cular repair compared to patients followed in an
ultrasound surveillance program. These data suggest
that early endovascular repair may be preferable to
surveillance and delay of aneurysm treatment until the
aneurysm enlarges or becomes symptomatic. It should
be noted that the great majority of UK patients with
small aneurysms who were randomized to undergo
ultrasound surveillance required surgical treatment of
their aneurysm at some later date. By the end of the
UK clinical trial in 1998, 327 of 527 surveillance
patients (62%) had undergone open surgical repair
and 19 patients (3.6%) had experienced aneurysm
rupture with a 1 year rupture rate of 1.6%. After three
more years of follow up, an additional 62 patients had
undergone open surgery and there were eight
additional ruptures with a rupture rate of 3.2% per
year. By August 2001, a total of 389 patients (74%) had
undergone surgical repair and only 33 patients (6% of
the surveillance cohort) were alive without having had
surgery and without aneurysm rupture.9 Thus, sur-
veillance did not effectively protect patients from the
risk of rupture and did not eliminate the need for
aneurysm treatment for most patients.
The prospective, randomized ADAM trial was
similar in design to the UK Small Aneurysm Trial
and reached similar conclusions regarding lack of long
term survival benefit for early open surgical repair of
small aneurysms.3 Among 567 patients with aneur-
ysms 4.0–5.4 cm in diameter who were randomized to
ultrasound surveillance, there were 11 aneurysm
ruptures (1.9%), seven fatal ruptures (1.2%) and 15
aneurysm related deaths (2.6%). Operative mortality
in the surveillance group was 2.1%. Almost all patients
in the surveillance group were men (99.6%) and the
age entry criteria for the trial was 50–79 years. Average
follow up time for all patients in the trial was 4.9 years,
significantly longer than the mean follow up time of
2.9 years for EVAR small aneurysm patients. However,
follow up time and total patient follow-up years for
the surveillance group was not reported and, there-
fore, end points could not be expressed in terms of 100
patient years. Thus, although we were able to select an
EVAR subgroup matched to ADAM inclusion criteria,
it was not possible to adjust for differences in length of
follow up and published data was insufficient for validEur J Vasc Endovasc Surg Vol 29, May 2005
C. K. Zarins et al.502comparisons of the endpoints of aneurysm rupture,
fatal rupture, aneurysm related death and survival.
The most reliable method to compare two treatment
strategies is a prospective randomized clinical trial.
Two such trials comparing endovascular aneurysm
repair to open surgical repair of large aneurysms have
recently been published.17,18 Both showed a significant
reduction in 30 day mortality with endovascular
repair. Our study suggests that patients with small
aneurysms who are treated with EVAR have a
significant reduction in the risk of fatal aneurysm
rupture and have improved survival compared to
ultrasound surveillance. However, these findings
should be confirmed with a prospective randomized
clinical trial. Our study further suggests that late all-
cause mortality, such as used in the UK and ADAM
trials, may not be a discriminating end-point when
comparing different treatment strategies for elderly
patients with aortic aneurysms. Aneurysm specific
endpoints such as aneurysm rupture, fatal rupture and
aneurysm related death may be better suited for this
purpose and should be used in future prospective
trials.Conclusion
Early endovascular repair of small abdominal aortic
aneurysms appears to significantly reduce the risk of
fatal rupture and aneurysm-related death and
improves overall patient survival compared to a
strategy of ultrasound surveillance of small aneur-
ysms. On the basis of information available at this
point in time, it appears that endovascular repair can
be supported as a safe and effective treatment for
selected patients with small aortic aneurysms.References
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